Adventris Pharmaceuticals

Adventris Pharmaceuticals is dedicated to developing innovative cancer vaccines. Their core technology addresses the challenge of effectively targeting oncogenes that typically elicit a weak immune response. The company's initial focus is on creating an "off-the-shelf" vaccine targeting KRAS, a prevalent oncogene found in many cancers. Adventris envisions a future where annual, broad-spectrum cancer vaccines are administered to adults, significantly reducing cancer-related mortality rates. For inquiries regarding their approach to cancer treatment and prevention, please contact them at contact@adventris.com.